Slimming jabs Mounjaro: the clinical evidence explained

What the SURMOUNT trial results actually showed, and why they matter

When people search for slimming jabs and land on Mounjaro, they usually want a straight answer on whether the weight loss is real. It is. The SURMOUNT-1 phase 3 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and found average body-weight reductions of roughly 15% at 5mg, 19.5% at 10mg, and around 20–21% at 15mg over 72 weeks, compared with about 3% in the placebo group. Those are clinically meaningful numbers, not rounding errors.

A later head-to-head trial, SURMOUNT-5, compared tirzepatide directly with semaglutide 2.4mg and found greater average weight loss with tirzepatide over 72 weeks. That evidence informed NICE's appraisal of tirzepatide (TA1026), published in December 2024, which recommended it for NHS use in eligible adults. The data sits on top of thousands of participants across the combined SURMOUNT and SURPASS programmes, robust by any standard for a weight-management medicine.

If you want to understand the broader tirzepatide landscape before deciding anything, the tirzepatide information page covers the mechanism and UK licensing in more detail. The results don't mean every person loses the same amount, biology, starting weight, dose reached and lifestyle changes all interact. But the floor of evidence is solid, and if you are researching what the slimming jab Mounjaro involves from a clinical standpoint, that trial record is the right place to start.

Who these slimming jabs are licensed for (and what the prescriber looks at

UK licensing for Mounjaro covers adults with a BMI of 30 or above, or 27 and above where at least one weight-related condition is present) conditions such as hypertension, high cholesterol, obstructive sleep apnoea, prediabetes or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI is the starting point; it is not the whole picture.

A prescriber reviews your full health history, current medicines, any contraindications and what you are actually hoping to achieve. People with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, or with certain gastrointestinal conditions, are not suitable candidates. Pregnancy, breastfeeding and actively trying to conceive are situations where Mounjaro is not recommended, and it is not licensed for anyone under 18.

The Mounjaro overview page sets out the full eligibility picture if you want to work through it before a consultation. Worth knowing: meeting the BMI threshold does not automatically mean approval. The prescriber makes that call based on the whole assessment, and that is exactly what should happen with a prescription medicine.

Side effects: what most people notice and what to watch for

The most common side effects are gastrointestinal. Nausea tends to arrive in the first week or two after starting or after a dose increase, and for most people it settles as the body adjusts. Vomiting, constipation, diarrhoea, reflux and fatigue appear regularly in trial data; injection-site reactions are also reported. None of this is unusual for a medicine that works partly by slowing gastric emptying.

There are less common but more serious signals to know. In January 2026 the MHRA issued a Drug Safety Update for GLP-1 medicines noting that acute pancreatitis (though infrequent) can be serious: severe stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention, not a wait-and-see approach. Gallbladder problems and dehydration from persistent vomiting or diarrhoea are also worth flagging to a prescriber quickly.

If you are on the oral contraceptive pill, your prescriber will explain the specific guidance for the first four weeks of Mounjaro treatment and after each dose increase, because tirzepatide can affect how the pill is absorbed. You can find a fuller safety picture on the NHS tirzepatide medicines page. Side effects are also reportable directly to the MHRA via the Yellow Card scheme. Any slimming jab should come with the clinical support to manage these, that is part of what aftercare means in practice.

Accessing Mounjaro as a private patient: what the process looks like

If you are wondering about NHS access, NICE has recommended tirzepatide but the rollout is phased and criteria are strict. Currently the NHS route requires a high BMI alongside multiple qualifying conditions, and many people either do not meet the thresholds yet or face a wait. Private prescription is the legal alternative, through a registered pharmacy following a genuine clinical assessment.

It is worth pausing here, because a lot of people arrive at this search feeling frustrated, waiting lists, GP conversations that went nowhere, information that is hard to verify. That frustration is legitimate. The honest answer is that private treatment through a regulated route is available now, but it requires the same clinical rigour as any other prescribing pathway. The cost context is worth understanding too; you can read about what drives Mounjaro pricing in the UK if that is on your mind before you start.

At nume, a GPhC-registered Independent Prescriber personally reviews every consultation the same day, not software. Once approved, treatment is dispatched the same day for free next-working-day delivery via DPD. The Mounjaro jabs page explains how the dispensing process works from that point, and if you are comparing providers you may also find it useful to read about getting Mounjaro through a slimming direct service to understand what that route involves. You can also read more about how we work as a service or explore all available weight-loss treatments before deciding. If you are ready to take the next step, start your free consultation and a prescriber will assess your suitability the same day.